Last updated: June 11, 2026
Daypro Alta clinical trials update, market analysis, and exclusivity-driven launch projections
Executive summary: No credible, uniquely identifiable public record links a drug product named “Daypro Alta” to a specific active ingredient, FDA application, clinical trial program, sponsor, or patent estate. Without a determinable drug identity (strength, dosage form, manufacturer, active moiety, NDA/BLA number, or clinicaltrials.gov listing), a clinical-trials update, market sizing, and exclusivity-based launch projection cannot be produced without fabricating facts.
What is “Daypro Alta” and what active ingredient is it?
Featured snippet answer: A definitive identification for “Daypro Alta” (active ingredient, dosage form, applicant, FDA application number) is not available in reliable public FDA or clinical-trials registries under that product name.
Is “Daypro Alta” a branded version of oxaprozin or a different NSAID?
Featured snippet answer: No verifiable mapping from “Daypro Alta” to a named NDA/BLA, Orange Book record, or clinicaltrials.gov sponsor/program is available from the provided information.
Which regulator filings correspond to “Daypro Alta”?
Featured snippet answer: No uniquely attributable FDA submission (NDA/BLA/505(b)(2)/ANDA) can be matched to the name “Daypro Alta.”
What clinical trials are ongoing or completed for Daypro Alta?
Featured snippet answer: No uniquely attributable clinical trial program can be matched to “Daypro Alta” under a known active ingredient and sponsor.
Are there Phase 1, Phase 2, Phase 3, or registrational studies?
Featured snippet answer: No identifiable Phase 1 through Phase 3 trial entries can be confirmed for “Daypro Alta” using the product name as provided.
What endpoints and design details are reported?
Featured snippet answer: No trial-level endpoint dataset can be tied to the name “Daypro Alta” without a verifiable sponsor and trial registry linkage.
How strong is the patent and exclusivity position for Daypro Alta?
Featured snippet answer: Patent and exclusivity analysis cannot be performed without an identifiable drug identity (active ingredient, NDA number, listed patents, and exclusivity codes).
What patents protect the drug substance or drug product?
Featured snippet answer: Not determinable for “Daypro Alta” without Orange Book mapping to a specific NDA.
When does exclusivity end for Daypro Alta?
Featured snippet answer: Not determinable without exclusivity listings and approval dates.
Is there Paragraph IV risk for generics or biosimilar competition?
Featured snippet answer: Not determinable without ANDA litigation/notice data tied to an identified NDA.
What is the Orange Book status of Daypro Alta?
Featured snippet answer: Orange Book status cannot be assigned to “Daypro Alta” because no verifiable Orange Book listing can be matched from the provided drug name alone.
Which patents are listed and in what categories?
Featured snippet answer: Not determinable.
Are there formulation patents, method-of-use patents, or manufacturing-process patents?
Featured snippet answer: Not determinable.
What market opportunity does Daypro Alta have, and how big is the addressable segment?
Featured snippet answer: A market model cannot be built without knowing the active ingredient, formulation, route, approved indication(s), patient population, pricing basis, and geography.
What are the competitive substitutes and market share dynamics?
Featured snippet answer: Not determinable without drug identity and indication.
What is the pricing framework for Daypro Alta (WAC, net price, payer mix)?
Featured snippet answer: Not determinable without a mapped NDC label and payer file proxy.
When could Daypro Alta face generic entry, and what launch scenarios are most likely?
Featured snippet answer: Generic entry timing depends on NDA exclusivity end date and Orange Book patent expiration. Neither can be established for “Daypro Alta” without an identifiable FDA record.
Does the program include 505(b)(2) or ANDA-relevant bridging?
Featured snippet answer: Not determinable.
How many barriers exist from formulation, method-of-use, and process patents?
Featured snippet answer: Not determinable.
How does Daypro Alta compare with competing drugs in the same class?
Featured snippet answer: Comparison cannot be performed because “Daypro Alta” active ingredient and indication are not determinable.
Which companies control the incumbency in the relevant therapeutic area?
Featured snippet answer: Not determinable.
What are the clinical differentiation claims that affect switching?
Featured snippet answer: Not determinable.
Key Takeaways
- “Daypro Alta” cannot be uniquely identified to an active ingredient, FDA approval record, clinical trial program, or patent estate from the information provided.
- Clinical-trials update, Orange Book/patent strength assessment, generic entry risk, and market projection would require a deterministic drug-to-record mapping that is not present here.
FAQs
- What FDA application type would “Daypro Alta” map to (NDA, 505(b)(2), ANDA)?
- How can market projections differ if “Daypro Alta” is immediate-release versus extended-release?
- What litigation patterns usually accompany NSAID brand-to-generic transitions?
- How do exclusivity waivers or consent decrees change generic entry timing?
- Which trial endpoints most influence NSAID labeling and payer acceptance (pain score, function, safety)?
References (APA)
- U.S. Food and Drug Administration. Drugs@FDA.
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- U.S. National Library of Medicine. ClinicalTrials.gov.
